Enjoy complimentary customisation on priority with our Enterprise License!
About erythropoietin
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.
Technavio's analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.
Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.
Technavio's report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.
Key vendors
• Chugai Pharmaceutical
• JCR Pharmaceuticals
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
Other prominent vendors
• Eisai
• Otsuka
• Taiho Pharmaceutical
• Takeda
Market driver
• Increased incidence of anemia due to illness
• For a full, detailed list, view our report
Market challenge
• High cost of therapy
• For a full, detailed list, view our report
Market trend
• Strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Part 01: Executive summary
Highlights
Part 02: Scope of the report
Market overview
Top-vendor offerings
Part 03: Market research methodology
Research methodology
Economic indicators
Part 04: introduction
Key market highlights
Part 05: Biosimilars/biologics industry
Overview
Emerging role of biosimilars
Factors influencing biosimilars / biologics market
Biosimilars: business and pricing strategy
Biosimilars industry point of view (providers, payers, buyers, vendors, regulatory bodies)
Part 06: japan- country snapshot
Socio-economic factors
Pharmaceutical industry in japan
Biologics / biosimilars market in japan
Regulatory landscape
Healthcare reform
Epo – addressable market in japan (epidemiology – oncology, ckd, hiv/aids, wound healing neurology)
Part 07: Global erythropoietin market
Part 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
Part 09: Market segmentation by application
End stage renal disease
Cancer
HIV
Wounds and neural disease
Part 10: Market segmentation by product type
First generation erythropoietin formulation
Second generation erythropoietin formulation
Biosimilars
Part 11: Market segmentation by end user
Hospitals
Retail outlets
Part 12: Market drivers
Part 13: Impact of drivers
Part 14: Market challenges
Part 15: Impact of drivers and challenges
Part 16: Market trends
Part 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
Part 18: Key vendor analysis
Chugai pharmaceuticals
Jcr pharmaceuticals
Kissei pharmaceutical
Kyowa hakko kirin
Part 19: Appendix
List of abbreviation
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.